<DOC>
	<DOCNO>NCT00122356</DOCNO>
	<brief_summary>The purpose study evaluate use oral bisphosphonate ( alendronate ) prevent bone loss postmenopausal woman early breast cancer receive anastrozole therapy , determine long alendronate treatment need .</brief_summary>
	<brief_title>Bisphosphonate Anastrozole Trial - Bone Maintenance Algorithm Assessment</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<criteria>Postmenopausal Adequately diagnose treated Stage IIIIa early breast cancer Oestrogen receptor and/or progesterone receptor positive breast cancer Eastern Cooperative Oncology Group ( ECOG ) performance status less equal 2 Hormone replacement therapy ( HRT ) must discontinue least 2 week prior registration Any prior tamoxifen take total 8 week less Any prior anastrozole take total 4 week less Anastrozole clinically indicate best adjuvant strategy Signed write informed consent Clinical radiological evidence distant spread disease Prior treatment bisphosphonates within past 12 month Prior treatment continuous systemic corticosteroid within past 12 month Prior use parathyroid hormone 1 week Prior use systemic sodium fluoride &gt; 3 month past 2 year Currently treat drug know affect skeleton Abnormal renal function ( serum creatinine great equal 265.2 mmol/L ) History disease influence bone metabolism . Patients lactose intolerance also exclude Delayed oesophageal empty stricture achalasia Hypersensitivity alendronate anastrozole Previous concomitant malignancy within past 5 year EXCEPT adequately treat basal squamous cell carcinoma skin situ carcinoma cervix AST/SGOT and/or ALT/SGPT &gt; 3 x ULN combination laboratory clinical abnormality indicate liver insufficiency Fracture due minimal trauma , demonstrate radiologically</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>